These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16130177)

  • 41. Enfuvirtide: a review of its use in the management of HIV infection.
    Oldfield V; Keating GM; Plosker G
    Drugs; 2005; 65(8):1139-60. PubMed ID: 15907147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 43. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The introduction of the fusion inhibitors in the HAART-regimens.
    Hasson H; Castagna A; Clementi M; Menzo S; Danise A; Lazzarin A
    New Microbiol; 2004 Apr; 27(2 Suppl 1):11-6. PubMed ID: 15646060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
    Hardy H; Skolnik PR
    Pharmacotherapy; 2004 Feb; 24(2):198-211. PubMed ID: 14998221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enfuvirtide is active against HIV type 1 group O.
    Poveda E; Barreiro P; Rodés B; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):583-5. PubMed ID: 15989465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Enfuvirtide: first drug of a new family of antiretroviral agents].
    Espona M; Ferrández O; Grau S; Carmona A
    Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discontinuation of the clinical development of fusion inhibitor T-1249.
    Martin-Carbonero L
    AIDS Rev; 2004; 6(1):61. PubMed ID: 15168742
    [No Abstract]   [Full Text] [Related]  

  • 50. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enfuvirtide: the first HIV fusion inhibitor.
    Lazzarin A
    Expert Opin Pharmacother; 2005 Mar; 6(3):453-64. PubMed ID: 15794736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
    Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
    J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).
    Manfredi R; Sabbatani S
    Curr Med Chem; 2006; 13(20):2369-84. PubMed ID: 16918361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enfurvirtide safety in human immunodeficiency virus-infected children.
    Baylor MS; Johann-Liang R
    Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309
    [No Abstract]   [Full Text] [Related]  

  • 56. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enfuvirtide for prophylaxis against HIV Infection.
    Ferranti S; Menichetti F
    N Engl J Med; 2003 Aug; 349(8):815. PubMed ID: 12930939
    [No Abstract]   [Full Text] [Related]  

  • 58. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 59. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current peptide HIV type-1 fusion inhibitors.
    Pang W; Tam SC; Zheng YT
    Antivir Chem Chemother; 2009 Sep; 20(1):1-18. PubMed ID: 19794228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.